The Zhitong Finance App learned that Kang Fang Biotech (09926) rose by more than 5%. As of press release, it had risen 5.26% to HK$85.1, with a turnover of HK$657 million.

According to the news, Kang Fang Biotech recently announced that Harmoni-GI1/AK112-309 was selected as Late-Breaking Abstract (LBA) as an oral report for the 2026 ESMO Conference Chairman Forum. The main researcher, Academician Zhou Jian, director of Zhongshan Hospital affiliated to Fudan University, gave a presentation. According to reports, Harmoni-GI1/AK112-309 (CTR20243164) is a randomized, controlled, double-blind, registered phase III clinical study that evaluates the comparison of evossi combined with chemotherapy in first-line treatment of advanced biliary tract cancer with Vallieu combined with chemotherapy. A total of 682 subjects were enrolled.

In August 2026, a pre-set mid-term analysis assessed by the Independent Data Monitoring Committee (IDMC) showed that the Harmoni-GI1/AK112-309 study reached the main end point of overall survival (OS) and obtained positive results with statistically significant clinical benefits; the study also reached all key secondary endpoints of progression-free survival (PFS) and objective response rate (ORR). The groundbreaking data from the Harmoni-GI1 study strongly supports the potential of evosil combination chemotherapy as a new standard treatment for advanced biliary tract cancer.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.